$LCTX Cashflow Statement | Understand Stock

$LCTX

$1.00 -$0.00 (0.31%) Close

$LCTX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss attributable to Lineage
Net income (loss) attributable to noncontrolling interest
Adjustments to reconcile net loss attributable to Lineage Cell Therapeutics, Inc. to net cash used in operating activities:
Gain on sale of marketable equity securities
Unrealized loss on marketable equity securities
Amortization of right-of-use assets
Loss on sale of marketable securities
Issuance costs for common stock warrant liabilities
Loss on impairment of intangible asset
Loss on marketable equity securities, net
Accretion of income on marketable debt securities
Gain on extinguishment of debt
Depreciation and amortization expense
Change in right-of-use assets and liabilities
Amortization of intangible assets
Stock-based compensation
Common stock issued for services
Change in unrealized (gain) loss on warrant liability
Gain on revaluation of warrant liability
Foreign currency remeasurement and other loss/(gain)
Change in fair value of warrant liability
Deferred income tax benefit
Gain on sale of assets
Foreign currency remeasurement and other loss
Foreign currency remeasurement
Changes in operating assets and liabilities:
Accounts receivable
Prepaid expenses and other current assets
Accounts payable and accrued liabilities
Deferred revenue and other liabilities
Deferred revenue and other liabilities (Note 3)
Deferred revenue

Net cash used in operating activities
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from the sale of marketable equity securities
Purchases of marketable debt securities
Maturities of marketable debt securities
Purchase of equipment
Proceeds from sale of assets
Proceeds from sale of OncoCyte common shares
Proceeds from the sale of HBL common shares
Net cash used in investing activities

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from employee options exercised
Proceeds from exercise of warrants
Payments for offering costs
Common shares received and retired for employee taxes paid
Proceeds from sale of common shares, net of offering costs
ATM
Direct Financing
Warrants Under Registered Direct Financing
Total proceeds from sale of common shares, net of offering costs
Payment of financed insurance premium
Payment of finance lease liabilities
Net cash provided by financing activities

Effect of exchange rate changes on cash, cash equivalents and restricted cash
NET DECREASE (INCREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH
At beginning of year
At end of year
CASH, CASH EQUIVALENTS AND RESTRICTED CASH:
At beginning of the period
At end of the period
SUPPLEMENTAL DISCLOSURES
Cash paid for interest
SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING AND INVESTINGACTIVITIES:
Receivable from sale of common shares in at the market offering
Financing costs in accounts payable and accrued liabilities
Property and equipment expenditures in accounts payable
Amortization of financing costs
Fair value of warrant liability recognized upon issuance in registered direct financing
Derivative warrant liability reclassified to share capital upon exercise of warrants
Financed insurance premium
Receivable from exercise of stock options

Reconciliation of cash, cash equivalents and restricted cash, end of period:
Cash and cash equivalents
Restricted cash included in deposits and other long-term assets (see Note 13 (Commitments and Contingencies))

Comments